{"id":"W2142466432","doi":"10.1016/s1470-2045(12)70560-0","title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":740,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Institute of Cancer Research; National Cancer Institute; Institut National Du Cancer; Sanofi; Roche; Bayer; AstraZeneca; Unicancer; Novartis; Pfizer; Amgen","keywords":"Medicine; Docetaxel; Androgen deprivation therapy; Prostate cancer; Internal medicine; Oncology; Estramustine; Clinical endpoint; Chemotherapy; Goserelin; Prostate-specific antigen; Urology; Cancer; Randomized controlled trial","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null}